Last update 08 May 2025

LEO-22811

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Psoriasis vulgaris
Originator Organization
Leo Pharma, Inc.Leo Pharma, Inc.
Active Organization-
Inactive Organization
Leo Pharma, Inc.Leo Pharma, Inc.
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with LEO-22811
NCT01211964
/ CompletedPhase 1
LEO 22811 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects
EUCTR2009-017858-12-FR
/ Not yet recruitingPhase 2
A phase 2a proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris
NCT01116895
/ CompletedPhase 2
An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris
100 Clinical Results associated with LEO-22811
Login to view more data
100 Translational Medicine associated with LEO-22811
Login to view more data
100 Patents (Medical) associated with LEO-22811
Login to view more data
100 Deals associated with LEO-22811
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Psoriasis vulgarisPhase 2
Canada
Leo Pharma, Inc.Leo Pharma, Inc.
01 May 2010
Psoriasis vulgarisPhase 2
France
Leo Pharma, Inc.Leo Pharma, Inc.
01 May 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01116895 (CTgov)
Phase 2
Psoriasis vulgaris
63
Placebo
(Placebo)
qajwrskqqr(jxjlpsqfon) = qezxqjmrqn usyjrmnybj (yzekidxnzn, njvmtcwanw - xevbislnfx)
View more
-
03 Oct 2018
(LEO 22811 0.5 mg)
qajwrskqqr(jxjlpsqfon) = ughkzmwbcf usyjrmnybj (yzekidxnzn, kivmixplcr - ndullbmmsx)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free